Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Animal Models

Abstract A016: Use of luminescent xenograft and 3D In vitro tumor models in pharmacology studies of chimeric antigen receptor-T (CAR-T) cells

Ruyi Li, Shanshan Gan, Leixin Zhang, Patrice Cuff, Zhuyao Wang and Thomas Broudy
Ruyi Li
1BioDuro LLC, Shanghai;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shanshan Gan
1BioDuro LLC, Shanghai;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leixin Zhang
1BioDuro LLC, Shanghai;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Cuff
2BioDuro LLC, San Diego, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhuyao Wang
1BioDuro LLC, Shanghai;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Broudy
2BioDuro LLC, San Diego, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-19-A016 Published December 2019
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA

Abstract

Chimeric antigen receptor-T (CAR-T) cell immunotherapy uses a patient’s T cells to engineer T cells with chimeric antigen receptors to attack their cancer cells. Recently the first two CAR-T therapies were approved by the U.S. Food and Drug Administration: Yescarta to treat lymphoma in adults and Kymriah to treat pediatric and young adult patients with acute lymphoblastic leukemia. With their significant efficacy shown in patients, more CAR-T therapies have begun to develop at the preclinical phases with new targets or alternative chimeric antigen designs. Here we demonstrate the use of xenograft mouse models to show the efficacy of CAR-T cells utilizing an orthotopic lymphoma and ovarian cancer subcutaneous models. In the first model, luciferase-labeled Raji (Raji-luc) cells were injected into immune-deficient B-NDG mice from Biocytogen, and 9 days after tumor inoculation, CAR-T 1 or CAR-T 2 were given to animals through a single IV injection. Approximately one week later, significant tumor growth inhibition was observed in both CAR-T cell treated groups. Additionally, at Day 37 post-tumor inoculation, all animals in the control group had died, while the CAR T treated group had a 75% survival rate. With the same batch of CAR-T cells as above, we tested their efficacy in BioDuro’s proprietary 3D culture method which is aligned to the human tumor microenvironment (3D-hTME). Raji-luc cells were mixed with CAR-T cells at Effector:Target (E: T) ratios of 1:0.5, 1:2 and 1:8, and then seeded into a semi-solid medium for 3D culture in a 96-well plate. The luminescent signals were read by and IVIS spectrum imager after 4- or 24-hours incubation at 37oC. Consistent with the in vivo result, the 3D-hTME model shows that CAR-T cells had an increasing killing effect on Raji-luc cells, with higher E:T ratio and increased incubation time. To test CAR-Ts in a solid tumor xenograft model, a similar study was completed in a luciferase-labeled SK-OV-3 (SK-OV-3-luc) subcutaneous xenograft. SK-OV-3-luc cells were inoculated subcutaneously into B-NDG mice. This was followed 9 days later by CAR-T treatment through a single IV injection. Tumor sizes were measured with caliper or by luminescent signal in mice with an IVIS spectrum imager. The results demonstrate from Day 20 on that animals treated with CAR-T cells had significantly smaller tumors as compared to control animals. In summary, utilizing xenograft models with luciferase-labeled cancer cell lines, we can investigate the efficacy of experimental CAR-T therapies to treat liquid and solid tumors. Additionally, the use of in vitro 3D-hTME culture shows promising results as a potential earlier-stage preclinical screen for the assessment of CAR T activity.

Citation Format: Ruyi Li, Shanshan Gan, Leixin Zhang, Patrice Cuff, Zhuyao Wang, Thomas Broudy. Use of luminescent xenograft and 3D In vitro tumor models in pharmacology studies of chimeric antigen receptor-T (CAR-T) cells [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr A016. doi:10.1158/1535-7163.TARG-19-A016

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 18 (12 Supplement)
December 2019
Volume 18, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A016: Use of luminescent xenograft and 3D In vitro tumor models in pharmacology studies of chimeric antigen receptor-T (CAR-T) cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A016: Use of luminescent xenograft and 3D In vitro tumor models in pharmacology studies of chimeric antigen receptor-T (CAR-T) cells
Ruyi Li, Shanshan Gan, Leixin Zhang, Patrice Cuff, Zhuyao Wang and Thomas Broudy
Mol Cancer Ther December 1 2019 (18) (12 Supplement) A016; DOI: 10.1158/1535-7163.TARG-19-A016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A016: Use of luminescent xenograft and 3D In vitro tumor models in pharmacology studies of chimeric antigen receptor-T (CAR-T) cells
Ruyi Li, Shanshan Gan, Leixin Zhang, Patrice Cuff, Zhuyao Wang and Thomas Broudy
Mol Cancer Ther December 1 2019 (18) (12 Supplement) A016; DOI: 10.1158/1535-7163.TARG-19-A016
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Animal Models

  • Abstract LB-A01: Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab
  • Abstract A017: Development and characterization of HER2+ T-DM1-resistant breast PDX models in athymic nude mice
Show more Animal Models

Animal Models: Poster Presentations - Proffered Abstracts

  • Abstract LB-A01: Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab
  • Abstract A017: Development and characterization of HER2+ T-DM1-resistant breast PDX models in athymic nude mice
  • Abstract A011: Preclinical models of breast cancer brain metastasis for drug efficacy studies
Show more Animal Models: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement